# Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes

> **NCT02583919** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 79 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** ISIS-GCGRRx- Dose Level 1
- **DRUG:** ISIS-GCGRRx- Dose Level 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02583919
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-12-15
- **Final completion:** 2017-05-11
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2018-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02583919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02583919, "Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02583919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*